Ensuring Timely Access to Generics Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 11, 2019)
Ensuring Timely Access to Generics Act of 2019
This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.
The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.
The FDA may establish a timeline for submitting petitions.
What just happenedApr 11, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateApr 11, 2019
- Apr 11, 2019IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Apr 11, 2019IntroReferral10000
Introduced in Senate